Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Bioequivalence Study of a Randomized, Open-label, Single Dose, Two-way Crossover Design With Two-period, Two-treatment and Two-sequence of Dapagliflozin Tablet 10 mg Relative to Forxiga® in Healthy Thai Volunteers Under Fasting Condition

NCT06233045 is registered in ClinicalTrials.gov with Bio-innova Co., Ltd as lead sponsor.

NCT NCT06233045
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06233045 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Bioequivalence Study of a Randomized, Open-label, Single Dose, Two-way Crossover Design With Two-period, Two-treatment and Two-sequence of Dapagliflozin Tablet 10 mg Relative to Forxiga® in Healthy Thai Volunteers Under Fasting Condition
Lead sponsor
Bio-innova Co., Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
July 23, 2024
Completion date
September 8, 2024
Enrollment
30 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy subjects